RESIDENCY Flashcards Preview

Pedia > RESIDENCY > Flashcards

Flashcards in RESIDENCY Deck (38)
Loading flashcards...
1
Q

When to do ABG after hooking to mech vent

A

Within an hour

2
Q

Mech vent: How to set TV

A

6-8cc/kg

3
Q

Mech vent: How to set FiO2

A

Begin wih 100, wean as tolerated

4
Q

Mech vent: How to set PEEP

A

Begin with 5

5
Q

ABG parameter to measure oxygenation

A

PO2

6
Q

ABG parameter to measure ventilation

A

PCO2

7
Q

Parameters to manipulate to alter oxygenation (PO2)

A

1) FiO2
2) PEEP
3) I-time

8
Q

Parameters to manipulate to alter ventilation (PCO2)

A

1) RR
2) TV
3) Shorten I-time to lengthen E-time

9
Q

Proper ET size

A

(Age/4) + 4 OR

10
Q

ET length

A

Size x 3 OR
Wt. + 6 OR
(Age/2) + 12

11
Q

Mech vent: How to set rate

A

Infant: 25-30/min
Child: 15-20/min
Teen: 10-14/min

12
Q

Incidence of hemophilia A

A

1/10,000 male births

13
Q

Incidence of hemophilia B

A

1/30,000 male births

14
Q

Symptomatic female carriers of hemophilia A

A

30%

15
Q

Factors that increase risk of inhibitor development

A

Surgery
Infection
Most important: Genetics (gene mutation)

16
Q

% factor activity goal in hemophilia in Phils in factor transfusion

A

60-80%

100% in developed countries

17
Q

% factor activity for adequate hemostasis (hemophilia)

A

30%

18
Q

How to screen for inhibitors in patients with hemophilia

A

Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)

19
Q

Indications for admission of hemophiliac patients

A

1) Life-threatening bleed (excluding hemarthroses)

2) Non-life-threatening bleed IF known to have inhibitor

20
Q

Phenobarbital, side effect (WOF when loading)

A

Respiratory depression

21
Q

Incidence of hemophilia A

A

1/10,000 male birthd

22
Q

Incidence of hemophilia B

A

1/30,000 male births

23
Q

Symptomatic female carriers of hemophilia A

A

30%

24
Q

Factors that increase risk of inhibitor development

A

Surgery
Infection
Most important: Genetics (gene mutation)

25
Q

% factor activity goal in hemophilia in Phils in factor transfusion

A

60-80%

100% in developed countries

26
Q

% factor activity for adequate hemostasis (hemophilia)

A

30%

27
Q

How to screen for inhibitors in patients with hemophilia

A

Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)

28
Q

Indications for admission of hemophiliac patients

A

1) Life-threatening bleed (excluding hemarthroses)

2) Non-life-threatening bleed IF known to have inhibitor

29
Q

Phenobarbital, side effect (WOF when loading)

A

Respiratory depression

30
Q

Incidence of hemophilia A

A

1/10,000 male birthd

31
Q

Incidence of hemophilia B

A

1/30,000 male births

32
Q

Symptomatic female carriers of hemophilia A

A

30%

33
Q

Factors that increase risk of inhibitor development

A

Surgery
Infection
Most important: Genetics (gene mutation)

34
Q

% factor activity goal in hemophilia in Phils in factor transfusion

A

60-80%

100% in developed countries

35
Q

% factor activity for adequate hemostasis (hemophilia)

A

30%

36
Q

How to screen for inhibitors in patients with hemophilia

A

Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)

37
Q

Indications for admission of hemophiliac patients

A

1) Life-threatening bleed (excluding hemarthroses)

2) Non-life-threatening bleed IF known to have inhibitor

38
Q

Phenobarbital, side effect (WOF when loading)

A

Respiratory depression